| 200 Clarendon Street +1 617 728 7100 Main +1 617 426 6567 Fax www.dechert.com
|
| JOSEPH R. FLEMING
joseph.fleming@dechert.com +1 617 728 7161 Direct +1 617 275 8392 Fax |
March 22, 2011
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Investment Management
100 F Street, N.E.
Washington, D.C. 20549-8626
RE: | H&Q Life Sciences Investors |
| Preliminary Proxy Statement on Schedule 14A |
| File No. 811-06565 |
Ladies and Gentlemen:
H&Q Life Sciences Investors (the “Company”) has today filed with the Securities and Exchange Commission a Preliminary Proxy Statement on Schedule 14A (the “Proxy Statement”) with respect to a Special Meeting of Shareholders of the Company. The Company intends to call the Special Meeting of Shareholders in connection with a proposal to amend the Company’s Declaration of Trust, as more fully described in the Proxy Statement.
If you have any questions or comments about the Proxy Statement, please feel free to contact the undersigned at 617.728.7161. Thank you for your cooperation and attention to this matter.
Sincerely,
/s/ Joseph R. Fleming, Esq. |
|
cc: Daniel R. Olmstead, Ph.D.
US Austin Boston Charlotte Hartford New York Orange County Philadelphia Princeton San Francisco Silicon Valley Washington DC EUROPE Brussels Dublin London Luxembourg Moscow Munich Paris ASIA Beijing Hong Kong